{"id":71484,"date":"2026-05-20T10:05:00","date_gmt":"2026-05-20T10:05:00","guid":{"rendered":"https:\/\/medsbase.com\/pnc-27\/"},"modified":"2026-05-21T07:14:09","modified_gmt":"2026-05-21T07:14:09","slug":"pnc-27","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/pnc-27\/","title":{"rendered":"PNC-27 (p53-HDM2 membr\u00e1nov\u011b c\u00edlen\u00fd chim\u00e9rick\u00fd peptid)"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f \u2014 Co je PNC-27?<\/h3>\n

PNC-27<\/strong> je syntetick\u00fd chim\u00e9rick\u00fd peptid (~32 aminokyselin) vyvinut\u00fd na Albert Einstein College of Medicine (Bowne, Pinto, Michl, Rauschmayer, Brower et\u00a0al.), kter\u00fd spojuje dv\u011b funk\u010dn\u00ed dom\u00e9ny: helix v\u00e1zaj\u00edc\u00ed HDM2<\/strong> odvozeno od zbytk\u016f 12\u201326 transaktiva\u010dn\u00ed dom\u00e9ny p53 (sekvence PPLSQETFSDLWKLL) a peptidu pro membr\u00e1novou rezidenci (MRP)<\/strong> p\u0159ipojen\u00e9ho k ukotven\u00ed a naru\u0161en\u00ed plazmatick\u00fdch membr\u00e1n n\u00e1dorov\u00fdch bun\u011bk. Mechanistick\u00fd p\u0159edpoklad je, \u017ee HDM2 (lidsk\u00fd homolog MDM2) je abnorm\u00e1ln\u011b exprimov\u00e1n na povrchu plazmatick\u00e9 membr\u00e1ny<\/em> n\u00e1dorov\u00fdch bun\u011bk \u2014 nejen v j\u00e1d\u0159e, kde norm\u00e1ln\u011b degraduje p53. PNC-27 v\u00e1\u017ee povrchov\u011b exponovan\u00fd HDM2, dom\u00e9na MRP n\u00e1sledn\u011b naru\u0161uje lipidovou dvojvrstvu a n\u00e1dorov\u00e9 bu\u0148ky podstupuj\u00ed rychlou membr\u00e1novou l\u00fdzu a nekrotickou bun\u011b\u010dnou smrt. Publikov\u00e1no u pankreatick\u00fdch, leukemick\u00fdch, prsn\u00edch n\u00e1dor\u016f a dal\u0161\u00edch model\u016f. Pouze pro laboratorn\u00ed v\u00fdzkum. N\u00e1dorov\u011b c\u00edlen\u00fd chim\u00e9rick\u00fd peptid naru\u0161uj\u00edc\u00ed membr\u00e1nu.<\/em><\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> Lyofilizovan\u00fd \u226599% HPLC-verifikovan\u00fd chim\u00e9rick\u00fd peptid PNC-27 \u00b7 COA dostupn\u00e9 na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 kur\u00fdrn\u00ed slu\u017eba pro v\u00fdzkumn\u00e9 pot\u0159eby \u00b7 1 400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
T\u0159\u00edda slou\u010denin<\/strong><\/td>\nSyntetick\u00fd ~32-aa chim\u00e9rick\u00fd peptid; n\u00e1dorov\u011b c\u00edlen\u00fd terapeutick\u00fd peptid naru\u0161uj\u00edc\u00ed membr\u00e1nu; chim\u00e9ra HDM2-vazebn\u00e9 helice a peptidu pro membr\u00e1novou rezidenci (MRP)<\/td>\n<\/tr>\n
Chemick\u00fd n\u00e1zev<\/strong><\/td>\nPNC-27 (Peptide Nuclear Construct 27; synonyma: p53-MRP chim\u00e9ra, p53(12-26)-MRP konstrukt)<\/td>\n<\/tr>\n
CAS \u010d\u00edslo<\/strong><\/td>\nV\u00fdzkumn\u00fd chim\u00e9rick\u00fd peptid \u2014 \u017e\u00e1dn\u00e9 jedno kanonick\u00e9 CAS; identifikace publikovanou sekvenc\u00ed a COA dodavatele<\/td>\n<\/tr>\n
item9<\/strong><\/td>\nN-termin\u00e1ln\u00ed HDM2-vazebn\u00e1 helice (transaktiva\u010dn\u00ed zbytky p53 12\u201326): PPLSQETFSDLWKLL<\/strong>; spojovac\u00ed sekvence; C-termin\u00e1ln\u00ed peptid pro membr\u00e1novou rezidenci (MRP, sekvence se m\u00edrn\u011b li\u0161\u00ed nap\u0159\u00ed\u010d publikovan\u00fdmi referencemi \u2014 v\u00fdzkumn\u00edci by m\u011bli konzultovat COA pro p\u0159esnou sekvenci \u0161ar\u017ee). Celkem ~32 aminokyselin.<\/td>\n<\/tr>\n
item7<\/strong><\/td>\n~3 800 Da (v z\u00e1vislosti na p\u0159esn\u00e9 sekvenci MRP)<\/td>\n<\/tr>\n
item2<\/strong><\/td>\n~32-zbytkov\u00fd chim\u00e9rick\u00fd peptid \u2014 sekven\u010dn\u011b odvozen\u00e1 p\u0159ibli\u017en\u00e1 MF C173<\/sub>H278<\/sub>N52<\/sub>O43<\/sub>S; publikovan\u00e1 molekulov\u00e1 hmotnost ~3 800 Da (v z\u00e1vislosti na p\u0159esn\u00e9m membr\u00e1nov\u011b-v\u00e1zaj\u00edc\u00edm peptidov\u00e9m linkeru; konzultujte \u0161ar\u017eov\u00fd COA).<\/td>\n<\/tr>\n
Mechanismus \u00fa\u010dinku<\/strong><\/td>\nSelektivn\u00ed l\u00fdza membr\u00e1ny n\u00e1dorov\u00fdch bun\u011bk<\/strong>. (1) PNC-27 se v\u00e1\u017ee na HDM2<\/strong> na plazmatick\u00e9 membr\u00e1n\u011b n\u00e1dorov\u00fdch bun\u011bk. Norm\u00e1ln\u00ed bu\u0148ky exprimuj\u00ed HDM2 pouze v j\u00e1d\u0159e (kde ubiquitinuje a degraduje p53, \u010d\u00edm\u017e reguluje hladiny p53); n\u00e1dorov\u00e9 bu\u0148ky abnorm\u00e1ln\u011b exprimuj\u00ed HDM2 na bun\u011b\u010dn\u00e9m povrchu \u2014 co\u017e je n\u00e1dorov\u011b specifick\u00fd marker. (2) Po nav\u00e1z\u00e1n\u00ed se membr\u00e1nov\u011b-v\u00e1zaj\u00edc\u00ed peptidov\u00e1 dom\u00e9na (MRP) vno\u0159\u00ed do lipidov\u00e9 dvojvrstvy. (3) Multimerizace nav\u00e1zan\u00fdch molekul PNC-27 vytvo\u0159\u00ed membr\u00e1nov\u00e9 p\u00f3ry \u2192 rychl\u00e1 nekrotick\u00e1 bun\u011b\u010dn\u00e1 smrt b\u011bhem minut a\u017e hodin. Mechanismus je nekrotick\u00e1 membr\u00e1nov\u00e1 l\u00fdza (NE klasick\u00e1 apopt\u00f3za) \u2014 co\u017e odli\u0161uje PNC-27 od antikancer\u00f3zn\u00edch peptid\u016f p\u016fsob\u00edc\u00edch p\u0159es kasp\u00e1zovou dr\u00e1hu.<\/td>\n<\/tr>\n
Selektivita v\u016f\u010di n\u00e1dorov\u00fdm bu\u0148k\u00e1m<\/strong><\/td>\nPublikovan\u00fd v\u00fdzkum prok\u00e1zal selektivn\u00ed usmrcov\u00e1n\u00ed n\u00e1dorov\u00fdch bun\u011bk u pankreatick\u00e9ho adenokarcinomu, AML a ALL leuk\u00e9mi\u00ed, karcinomu prsu, prostaty, melanomu a dal\u0161\u00edch n\u00e1dorov\u00fdch model\u016f \u2014 p\u0159i zachov\u00e1n\u00ed odpov\u00eddaj\u00edc\u00edch kontrol norm\u00e1ln\u00edch bun\u011bk, kter\u00e9 nemaj\u00ed expresi HDM2 na povrchu.<\/td>\n<\/tr>\n
item11<\/strong><\/td>\nLyofilizovan\u00fd b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd pr\u00e1\u0161ek; jednor\u00e1zov\u00e9 v\u00fdzkumn\u00e9 lahvi\u010dky<\/td>\n<\/tr>\n
item13<\/strong><\/td>\n\u226599% (ov\u011b\u0159eno HPLC, COA na vy\u017e\u00e1d\u00e1n\u00ed); MALDI-TOF hmotnostn\u011b potvrzeno na chim\u00e9rou specifick\u00e9 molekulov\u00e9 hmotnosti<\/td>\n<\/tr>\n
Skladov\u00e1n\u00ed<\/strong><\/td>\nLyofilizovan\u00fd: kr\u00e1tkodob\u011b 2\u20138 \u00b0C, dlouhodob\u011b \u221220 \u00b0C. Rekonstituovan\u00fd: 2\u20138 \u00b0C, pou\u017e\u00edt do 30 dn\u016f. Vyvarujte se opakovan\u00e9ho zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed.<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nPouze pro laboratorn\u00ed v\u00fdzkum. Nepou\u017e\u00edvat pro hum\u00e1nn\u00ed nebo veterin\u00e1rn\u00ed diagnostick\u00e9 \u010di terapeutick\u00e9 \u00fa\u010dely. PNC-27 je preklinick\u00fd v\u00fdzkumn\u00fd n\u00e1stroj, kter\u00fd nepro\u0161el form\u00e1ln\u00edm klinick\u00fdm v\u00fdvojem. Nen\u00ed na seznamu zak\u00e1zan\u00fdch l\u00e1tek WADA.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Mechanismus \u00fa\u010dinku \u2014 HDM2-c\u00edlen\u00e1 membr\u00e1nov\u00e1 l\u00fdza<\/h2>\n

PNC-27 byl vyvinut skupinou Bowne \/ Pinto \/ Michl \/ Rauschmayer na Albert Einstein College of Medicine jako p\u0159\u00edklad chim\u00e9rick\u00e9ho peptidov\u00e9ho l\u00e9\u010debn\u00e9ho designu<\/strong> aplikovan\u00e9ho v onkologii \u2014 kombinuj\u00edc\u00edho n\u00e1dorov\u011b c\u00edlenou dom\u00e9nu (p53 odvozenou HDM2-vazebnou helisu) s generickou zab\u00edjej\u00edc\u00ed dom\u00e9nou (membr\u00e1nov\u011b-v\u00e1zaj\u00edc\u00edm peptidem). Designov\u00e1 logika:<\/p>\n